<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7450</journal-id>
<journal-title><![CDATA[Revista Colombiana de Psiquiatría]]></journal-title>
<abbrev-journal-title><![CDATA[rev.colomb.psiquiatr.]]></abbrev-journal-title>
<issn>0034-7450</issn>
<publisher>
<publisher-name><![CDATA[Asociacion Colombiana de Psiquiatria.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-74502017000100050</article-id>
<article-id pub-id-type="doi">10.1016/j.rcpeng.2017.03.002</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Isotretinoin therapy for acne vulgaris and first episode psychosis in an adolescent patient]]></article-title>
<article-title xml:lang="es"><![CDATA[Primer episodio psicótico en adolescente con acné vulgar y tratamiento con isotretinoína]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valderrama]]></surname>
<given-names><![CDATA[Felipe]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Restrepo]]></surname>
<given-names><![CDATA[Diana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad CES Departamento de Psiquiatría ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad CES  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2017</year>
</pub-date>
<volume>46</volume>
<numero>1</numero>
<fpage>50</fpage>
<lpage>54</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0034-74502017000100050&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0034-74502017000100050&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0034-74502017000100050&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Isotretinoin is a member of the retinoid family of drugs, and has been used for the treatment of severe acne. Its use has been associated with various psychiatric and behavioural symptoms.  Methodology: A case report and a non-systematic review of the literature are presented. Results: The case concerns a 13 year-old adolescent with insomnia, delusions, and auditory hallucinations, after two months of treatment with isotretinoin. The patient was admitted to hospital, where the use of psychoactive drugs and systemic disease that could explain the psychotic symptoms are ruled out. After two weeks of stopping the isotretinoin and starting with treatment with olanzapine 10 mg per day, there was complete remission of the psychotic symptoms.  Discussion: On the onset of psychotic symptoms in an adolescent with no prior personal or family history of mental illness, the diagnosis of a secondary psychosis needs to be considered.  Conclusion: Clinicians would benefit from knowing the psychiatric symptoms that could be associated with the use of this drug, as well as its suspension and specific treatment for emerging psychotic illness.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: La Isotreitonina, un medicamento de la familia de los retinoides ha sido utilizada para el tratamiento del acné severo. Su uso ha sido asociado con diversos síntomas psiquiátricos de tipo afectivo, psicótico y comportamental.  Metodología:  Reporte de caso y revisión no sistemática de la literatura relevante.  Resultados:  Hombre adolescente de 13 anos con insomnio, ideas delirantes, alucinaciones auditivas, luego de dos meses de tratamiento con isotretinoina. El paciente es hospital izado, se descartó el consumo de drogas psicoactivas y enfermedad sistémica que explicaran los síntomas psicóticos. Luego de dos semanas de suspender la isotretinoina y recibir tratamiento con olanzapina 10 mg al día remitieron los síntomas psicóticos.  Discusión: El inicio de síntomas psicóticos en un adolescente sin antecedentes personales ni familiares de enfermedad mental exige considerar el diagnósitico de psicosis secundaria. Los clínicos se benefician de conocer los síntomas psiquiátricos que se pueden asociar con este medicamento, considerar la suspensión y el tratamiento específico para la psicopatología emergente.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Psychotic disorders]]></kwd>
<kwd lng="en"><![CDATA[isotretinoin]]></kwd>
<kwd lng="en"><![CDATA[acne vulgaris]]></kwd>
<kwd lng="en"><![CDATA[drug-related side effects and adverse reactions]]></kwd>
<kwd lng="es"><![CDATA[Psicosis]]></kwd>
<kwd lng="es"><![CDATA[isoteretinoina]]></kwd>
<kwd lng="es"><![CDATA[acné vulgar]]></kwd>
<kwd lng="es"><![CDATA[efectos colaterales y reacciones adversas relacionados con medicamentos]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agarwal]]></surname>
<given-names><![CDATA[US]]></given-names>
</name>
<name>
<surname><![CDATA[Besarwal]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Bhola]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral isotretinoin in different dose regimens for acne vulgaris a randomized comparative trial]]></article-title>
<source><![CDATA[Indian J Dermatol Venereol Leprol]]></source>
<year>2011</year>
<volume>77</volume>
<page-range>688-94</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ludot]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mouchabac]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inter-relationships between isotretinoin treatment and psychiatric disorders depression, bipolar disorder, anxiety, psychosis and suicide risks]]></article-title>
<source><![CDATA[World J Psychiatry]]></source>
<year>2015</year>
<volume>22</volume>
<page-range>222-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Segmiller]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Rüther]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Linhardt]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dehning]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mõller]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Zetzsche]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychosis during treatment with isotretinoin]]></article-title>
<source><![CDATA[Ther Adv Psychopharmacol]]></source>
<year>2013</year>
<volume>3</volume>
<page-range>244</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strahan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Raimer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Isotretinoin and the controversy of psychiatric adverse effects]]></article-title>
<source><![CDATA[Int J Dermatol]]></source>
<year>2006</year>
<volume>45</volume>
<page-range>789-99</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hazen]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Carney]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Depression - a side effect of 13-cis-retinoic acid therapy]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>1983</year>
<volume>9</volume>
<page-range>278-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poblete]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Herskovic]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Pedro]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Crisis de pánico en un paciente con acné tratado con isotretinoína Caso clínico]]></article-title>
<source><![CDATA[Rev Méd Chile]]></source>
<year>2006</year>
<volume>134</volume>
<page-range>1565-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rus-Calafell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lemos-Giraldez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esquizofrenia y otros trastornos psicóticos principales cambios del DSM-5]]></article-title>
<source><![CDATA[Rev Iberoam Psicosom]]></source>
<year>2014</year>
<volume>111</volume>
<page-range>89-93</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lohr]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Birmaher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychotic disorders]]></article-title>
<source><![CDATA[Child Adolescent Psychiatr Clin N Am]]></source>
<year>1995</year>
<volume>4</volume>
<page-range>237-54</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bunk]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Eggers]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Klapal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Symptom dimensions in the course of childhood-onset schizophrenia]]></article-title>
<source><![CDATA[Eur Child Adolesc Psychiatry]]></source>
<year>1999</year>
<numero>^s8</numero>
<issue>^s8</issue>
<supplement>8</supplement>
<page-range>21-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McClellan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[McCurry]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Snell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[DuBose]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early-onset psychotic disorders course and outcome over a 2-year period]]></article-title>
<source><![CDATA[J Am Acad Child Adolesc Psychiatry]]></source>
<year>1999</year>
<volume>38</volume>
<page-range>1380-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parnas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[From predisposition to psychosis: progression of symptoms in schizophrenia]]></article-title>
<source><![CDATA[Acta Psychiatr Scand]]></source>
<year>1999</year>
<numero>^s9</numero>
<issue>^s9</issue>
<supplement>9</supplement>
<page-range>20-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rajaprabhakaran]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Arndt]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Flaum]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Andreasen]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Premorbid adjustment as a predicto of phenomenological and neurobiological indices in schizophrenia]]></article-title>
<source><![CDATA[Schizophr Res]]></source>
<year>1995</year>
<volume>16</volume>
<page-range>189-97</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nicolson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rapoport]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Childhood-onset schizophrenia rare but worth studying]]></article-title>
<source><![CDATA[Biol Psychiatry]]></source>
<year>1999</year>
<volume>46</volume>
<page-range>1418-28</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&amp;apos;Donoghue]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lyne]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Madigan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[O&amp;apos;Callaghan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Environmental factors and the age at onset in first episode psychosis]]></article-title>
<source><![CDATA[Schizophr Res]]></source>
<year>2015</year>
<volume>168</volume>
<page-range>106-12</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cumming]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Organic psychoses Delusional disorders and secondary mania]]></article-title>
<source><![CDATA[Psychatr Clin N Am]]></source>
<year>1986</year>
<volume>9</volume>
<page-range>293-311</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association or causation]]></article-title>
<source><![CDATA[Proc R Soc Med]]></source>
<year>1965</year>
<volume>58</volume>
<page-range>295-300</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rajagopal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute psychosis induced by isotretinoin]]></article-title>
<source><![CDATA[Indian J Psychiatry]]></source>
<year>2014</year>
<volume>56</volume>
<page-range>295-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barak]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wohl]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Greenberg]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bar Dayan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shoval]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Affective psychosis following Accutane (isotretinoin) treatment]]></article-title>
<source><![CDATA[Int Clin Psychopharmacol]]></source>
<year>2005</year>
<volume>20</volume>
<page-range>39-41</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marqueling]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Zane]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Depression and suicidal behavior in acne patients treated with isotretinoin a systematic review]]></article-title>
<source><![CDATA[Semin Cutan Med Surg]]></source>
<year>2005</year>
<volume>24</volume>
<page-range>92-102</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schaffer]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Schaffer]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Hunter]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychiatric reactions to isotretinoin in patients with bipolar disorder]]></article-title>
<source><![CDATA[J Affect Disord]]></source>
<year>2010</year>
<volume>122</volume>
<page-range>306-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yesilova]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kaya]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Alpak]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of isotretinoin on obsessive compulsive symptoms, depression, and anxiety in patients with acne vulgaris]]></article-title>
<source><![CDATA[J Dermatol Treat]]></source>
<year>2012</year>
<volume>23</volume>
<page-range>268-71</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of retinoid signalling in the adult brain]]></article-title>
<source><![CDATA[Prog Neurobiol]]></source>
<year>2005</year>
<volume>75</volume>
<page-range>275-93</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bremner]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Shearer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[McCaffery]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retinoic acid and affective disorders the evidence for an association]]></article-title>
<source><![CDATA[J Clin Psychiatry]]></source>
<year>2012</year>
<volume>73</volume>
<page-range>37-50</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meng]]></surname>
<given-names><![CDATA[QY]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[XN]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Swaab]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distribution of retinoic acid receptor-alfa immunoreactivity in the human hypothalamus]]></article-title>
<source><![CDATA[Neuroscience]]></source>
<year>2011</year>
<volume>174</volume>
<page-range>132-42</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Una ceremonia estadística para identificar factores de riesgo]]></article-title>
<source><![CDATA[Salud Colectiva]]></source>
<year>2005</year>
<page-range>309-22</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
